KR102332835B1 - 프로모터 조성물 - Google Patents

프로모터 조성물 Download PDF

Info

Publication number
KR102332835B1
KR102332835B1 KR1020157029169A KR20157029169A KR102332835B1 KR 102332835 B1 KR102332835 B1 KR 102332835B1 KR 1020157029169 A KR1020157029169 A KR 1020157029169A KR 20157029169 A KR20157029169 A KR 20157029169A KR 102332835 B1 KR102332835 B1 KR 102332835B1
Authority
KR
South Korea
Prior art keywords
seq
cell
promoter
expression
expression cassette
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020157029169A
Other languages
English (en)
Korean (ko)
Other versions
KR20150129001A (ko
Inventor
비벌리 엘. 데이빗슨
에드가르도 로드리게즈
알레한드로 마스 몬티스
Original Assignee
유니버시티 오브 아이오와 리써치 파운데이션
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 유니버시티 오브 아이오와 리써치 파운데이션 filed Critical 유니버시티 오브 아이오와 리써치 파운데이션
Publication of KR20150129001A publication Critical patent/KR20150129001A/ko
Application granted granted Critical
Publication of KR102332835B1 publication Critical patent/KR102332835B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
KR1020157029169A 2013-03-15 2014-03-06 프로모터 조성물 Active KR102332835B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361794818P 2013-03-15 2013-03-15
US61/794,818 2013-03-15
PCT/US2014/021357 WO2014149882A1 (en) 2013-03-15 2014-03-06 Promoter compositions

Publications (2)

Publication Number Publication Date
KR20150129001A KR20150129001A (ko) 2015-11-18
KR102332835B1 true KR102332835B1 (ko) 2021-11-29

Family

ID=51580666

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020157029169A Active KR102332835B1 (ko) 2013-03-15 2014-03-06 프로모터 조성물

Country Status (14)

Country Link
US (1) US10105450B2 (https=)
EP (1) EP2970969B1 (https=)
JP (1) JP6473438B2 (https=)
KR (1) KR102332835B1 (https=)
CN (1) CN105358690B (https=)
AU (1) AU2014237759B2 (https=)
BR (1) BR112015022885A2 (https=)
CA (1) CA2906315C (https=)
ES (1) ES2809479T3 (https=)
IL (1) IL241667B (https=)
MX (1) MX373848B (https=)
RU (1) RU2742435C2 (https=)
WO (1) WO2014149882A1 (https=)
ZA (1) ZA201507439B (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6473079B2 (ja) * 2012-05-02 2019-02-20 ライフ テクノロジーズ コーポレーション 高密度増殖およびトランスフェクション培地並びに発現増強物質の固有の組み合わせを用いる、哺乳類細胞における高収率一過性発現

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5139941A (en) 1985-10-31 1992-08-18 University Of Florida Research Foundation, Inc. AAV transduction vectors
US7205146B1 (en) * 2000-06-14 2007-04-17 Oscient Pharmaceuticals Corporation Nucleotide and amino acid sequences relating to respiratory diseases and obesity
RU2192884C2 (ru) * 2000-11-09 2002-11-20 Государственное учреждение Научно-исследовательский институт клинической иммунологии СО РАМН Вакцина для стимуляции противоопухолевого иммунитета
US7193069B2 (en) 2002-03-22 2007-03-20 Research Association For Biotechnology Full-length cDNA
JP2005237384A (ja) * 2002-03-22 2005-09-08 Research Association For Biotechnology 新規な全長ｃＤＮＡ
JP2004008216A (ja) * 2002-03-22 2004-01-15 Research Association For Biotechnology 新規な全長ｃＤＮＡ
EP1707640A1 (en) * 2005-04-01 2006-10-04 Leiden University Medical Centre (LUMC) acting on behalf of the Academic Hospital Leiden Method of screening for the presence of a genetic defect associated with deep venous thrombosis
ITRM20050475A1 (it) * 2005-09-19 2007-03-20 Univ Degli Studi Genova Sequenze trascritte da rna polimerasi iii tipo iii e loro uso.
CA2652975A1 (en) * 2006-05-31 2007-12-13 Orion Genomics Llc Gene methylation in cancer diagnosis
WO2008073303A2 (en) * 2006-12-07 2008-06-19 Switchgear Genomics Transcriptional regulatory elements of biological pathways, tools, and methods
EP2152873A2 (en) * 2007-03-16 2010-02-17 Biorigen S.r.l Gene expression regulation technology and noncoding rnas for diagnosis and therapy
ES2334608B1 (es) * 2007-11-13 2011-01-24 Universidad Autonoma De Madrid Metodo para la identificacion de compuestos que inducen o inhiben estres de reticulo endoplasmatico o estres oxidativo.
EP3093351B1 (en) * 2008-07-09 2018-04-18 Celera Corporation Genetic polymorphisms associated with cardiovascular diseases, methods of detection and uses thereof
US8815779B2 (en) * 2009-09-16 2014-08-26 SwitchGear Genomics, Inc. Transcription biomarkers of biological responses and methods

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
HUMAN GENE THERAPY, vol. 22, pp1143-1153 (2011.09). 1부.*

Also Published As

Publication number Publication date
CA2906315A1 (en) 2014-09-25
US10105450B2 (en) 2018-10-23
JP6473438B2 (ja) 2019-02-20
CN105358690B (zh) 2019-12-31
MX2015013036A (es) 2016-05-18
WO2014149882A1 (en) 2014-09-25
RU2015144309A (ru) 2017-04-24
JP2016512028A (ja) 2016-04-25
KR20150129001A (ko) 2015-11-18
AU2014237759B2 (en) 2020-02-27
RU2742435C2 (ru) 2021-02-05
AU2014237759A1 (en) 2015-10-22
EP2970969A1 (en) 2016-01-20
CN105358690A (zh) 2016-02-24
IL241667B (en) 2021-03-25
EP2970969A4 (en) 2016-11-16
EP2970969B1 (en) 2020-05-06
ES2809479T3 (es) 2021-03-04
US20160022837A1 (en) 2016-01-28
HK1220486A1 (zh) 2017-05-05
CA2906315C (en) 2022-12-13
BR112015022885A2 (pt) 2017-11-07
MX373848B (es) 2020-03-26
ZA201507439B (en) 2022-03-30
RU2015144309A3 (https=) 2018-03-13

Similar Documents

Publication Publication Date Title
JP7452953B2 (ja) １色覚および他の疾患の治療のためのプロモーター、発現カセット、ベクター、キット、ならびに方法
KR102167668B1 (ko) 고 형질도입 효율 raav 벡터, 조성물 및 사용 방법
JP6509182B2 (ja) １色覚および他の疾患の治療のためのプロモーター、発現カセット、ベクター、キット、ならびに方法
US20240067984A1 (en) Triple function adeno-associated virus (aav)vectors for the treatment of c9orf72 associated diseases
EP2871239A9 (en) Cell capable of producing adeno-associated virus vector
CN112512595A (zh) 心脏、骨骼肌和肌肉干细胞中的体内同源性定向修复
CN121358753A (zh) 用于递送有效载荷的含rgd的肽
KR102332835B1 (ko) 프로모터 조성물
JP2023507174A (ja) Ｄｍｄ変異の修正のための方法及び組成物
TW202444916A (zh) 具有改良runx3基因表現之腺相關病毒複合體及其用於預防或治療kras突變肺癌之用途
HK1220486B (en) Promoter compositions
WO2025019358A2 (en) Mini-promoter compositions
US20220380812A1 (en) Crispr/cas9 system as an agent for inhibition of polyoma jc infection

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20151014

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20190306

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20200326

Patent event code: PE09021S01D

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20210226

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20210830

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20211125

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20211125

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
PR1001 Payment of annual fee

Payment date: 20241107

Start annual number: 4

End annual number: 4